Get started
Author

Tatiana Terrot

Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation
2019 · David Conen, Nicolas Rodondi, et al. · Journal of the American College of Cardiology · 233
PDF
Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2
2021 · Jun Siong Low, Daniela Vaqueirinho, et al. · Science · 133
Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland
2020 · Luca Piccoli, Paolo Ferrari, et al. · The Lancet Regional Health - Europe · 88
Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
2021 · Ilaria Colombo, Sofia Genta, et al. · Clinical Cancer Research · 36
PDF
Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients
2022 · Jessica Bassi, Olivier Giannini, et al. · PLoS ONE · 33
PDF
Long-term risk of adverse outcomes according to atrial fibrillation type
2022 · Steffen Blum, Stefanie Aeschbacher, et al. · Scientific Reports · 21
PDF
Heart rate variability and stroke or systemic embolism in patients with atrial fibrillation
2024 · Peter Hämmerle, Stefanie Aeschbacher, et al. · Heart Rhythm · 17
Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape
2022 · Roberta Marzi, Jessica Bassi, et al. · iScience · 12
PDF
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas
2021 · Maria C. Pirosa, Lu Zhang, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 9
Infusion Speed-Escalation Trial To Give Full-Dose Rituximab in One Hour without Steroids Pre-Medication.
2005 · Michele Ghielmini, Laura Negretti, et al. · Blood · 8
Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2
2021 · JS Low, D Vaqueirinho, et al. · immuneACCESS · 7
The importance of a healthy lifestyle to prevent mental health problems during crisis situations: evidence from Corona Immunitas Ticino
2024 · Giovanna Pedroni, Anne-Linda Camerini, et al. · Journal of Public Health · 6
PDF
568P Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours
2020 · I. Colombo, S. Genta, et al. · Annals of Oncology · 4
PDF
Ischemic brain infarcts, white matter hyperintensities, and cognitive impairment are increased in patients with Atrial Fibrillation
2026 · Philipp Krisai, Stefanie Aeschbacher, et al. · Communications Medicine · 1
PDF
Prevalence of SARS-CoV-2 infection and impact of vaccination in dialysis patients over two years of the pandemic
2023 · Paolo Hitz, Alberto Pagnamenta, et al. · Journal of Nephrology · 1
PDF
Barriers to implementing and conducting clinical trials in Switzerland - a mixed-methods study of Swiss physicians
2026 · Claudia Becherer, Samia Abed Maillard, et al. · OSF Preprints (OSF Preprints)
Table S1, Table S2, Table S3 from Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
2023 · Ilaria Colombo, Sofia Genta, et al.
Data from Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
2023 · Ilaria Colombo, Sofia Genta, et al.
Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape
2022 · Marzi, Roberta, Bassi, Jessica, et al. · Zurich Open Repository and Archive (University of Zurich)
Strategie di un'organizzazione per la gestione della qualità nei progetti di ricerca clinica
2016 · Tatiana Terrot
Abstract CT402: A phase I study of inotuzumab ozogamicin (IO) in combination with temsirolimus (T) in patients (pts) with relapsed or refractory (R/R) CD22-positive (pos) B-cell non-Hodgkin lymphomas (NHL)
2014 · Anastasios Stathis, Felicitas Hitz, et al. · Cancer Research
Works count: 21
Citation count: 609
H-index: 9
I10-index: 8
Year
Topic
Type